© 2024 MJH Life Sciences™ and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.
Ryan McDonald, Associate Editorial Director for CURE®, has been with the team since February 2020 and has previously covered medical news across several specialties prior to joining MJH Life Sciences. He is a graduate of Temple University, where he studied journalism and minored in political science and history. He considers himself a craft beer snob and would like to open a brewery in the future. During his spare time, he can be found rooting for all major Philadelphia sports teams. Follow Ryan on Twitter @RMcDonald11 or email him at rmcdonald@curetoday.com.
CURE® compiled a roundup of several recent news and updates involving quality of life improvements that patients with cancer may have missed.
There have recently been several updates regarding the quality of life of patients receiving treatment for various cancers. Here, CURE® looks back at some news and updates surrounding quality of life improvements that patients may have missed.
Not only did a three-step intervention improve survival rates in patients with high-risk hematologic malignancies, but patients also reported better physical and mental health afterward. READ MORE.
Patients with aggressive lymphoma tended to have major improvements in quality of life (QOL) after one year, compared to baseline QOL at diagnosis. Then, QOL increases continued upward for years to come. READ MORE.
Keytruda (pembrolizumab) in combination with Avastin (bevacizumab) and oral metronomic cyclophosphamide demonstrated improved efficacy, safety and quality of life in patients with recurrent platinum-sensitive, platinum-resistant, or refectory epithelial ovarian, fallopian tube or primary peritoneal cancer. READ MORE.
Patients with ALK-positive non-small cell lung cancer who received Lorbrena reported better quality of life and had longer progression-free survival than patients who received Xalkori. READ MORE.
In this episode of the “CURE Talks Cancer” podcast, one patient discusses what his journey with skin cancer has been like, as well as his decision to switch to a new therapy once his previous therapy stopped working. He also offers others facing similar situation advice and chronicles why he’s focused on quality rather than quantity. LISTEN HERE.
Quality of life improved in patients treated with Darzalex, Revlimid and dexamethasone compared with Revlimid and dexamethasone, and were present regardless of age, functional status and the depth of their treatment response. READ MORE.
The researchers concluded that the overall low health-related quality of life scores for young colorectal cancer survivors in the categories of social and functional well-being should be targeted by appropriate methods, which could include counseling and quality of life interventions. READ MORE.
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Related Content: